

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6467767

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	HENLIX BIOTECH CO., LTD.	07/26/2020
RECEIVING PARTY DATA		
Name:	SHANGHAI HENLIUS BIOTECH, INC.	
Street Address:	ROOM 303, 304, BLOCK 7, NO. 1999 ZHANGHENG ROAD	
Internal Address:	CHINA (SHANGHAI) PILOT FREE TRADE ZONE	
City:	SHANGHAI	
State/Country:	CHINA	
Postal Code:	201210	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	10584171
CORRESPONDENCE DATA		
Fax Number:	(650)494-0792	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6508135926	
Email:	drovetti@mofo.com	
Correspondent Name:	CHRISTINA ONUFRYK	
Address Line 1:	MORRISON & FOERSTER LLP	
Address Line 2:	755 PAGE MILL ROAD	
Address Line 4:	PALO ALTO, CALIFORNIA 94304	
ATTORNEY DOCKET NUMBER:	71990-20001.00	
NAME OF SUBMITTER:	CHRISTINA ONUFRYK	
SIGNATURE:	/PLEASE E-SIGN/	
DATE SIGNED:	12/23/2020	
Total Attachments: 2		
source=Assignment for Patent 10,584,171-signed#page1.tif		
source=Assignment for Patent 10,584,171-signed#page2.tif		

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: Henlix Biotech Co., Ltd.

Address: 5F., No. 36. Ln. 15, Sec. 6 Minquan E. Rd.

Taipei 11494, Taiwan

A juristic entity duly organized under and pursuant to the laws of: Taiwan

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the U.S. patent application identified below:

Patent No. 10,584,171 Issue Date: March 10, 2020

Title: ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ANTIBODIES

This Assignment is to:

Assignee: Shanghai Henlius Biotech, Inc.

Address: Room 303, 304, Block 7, No. 1999 Zhangheng Road,

China (Shanghai) Pilot Free Trade Zone,

Shanghai 201210

China

A juristic entity duly organized under and pursuant to the laws of: China

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent application and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and

sf-4395721

entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

3. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.


4. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: 26 July 2020

Signature: /



Name: Zihou Yan
Title: Chairman of the Board
Company: Henlix Biotech Co., Ltd.

ASSIGNEE:

Date: 26 July 2020

Signature: /



Name: Xinjun Guo
Title: Senior Vice President
Company: Shanghai Henlius Biotech, Inc.